TrialClinical cancer research : an official journal of the American Association for Cancer Research2011

Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.

Sahar A Saddoughi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.